AbbVie Inc. (LON:0QCV)

London flag London · Delayed Price · Currency is GBP · Price in USD
194.47
+3.96 (2.08%)
At close: Aug 1, 2025
2.08%
Market Cap260.33B
Revenue (ttm)42.57B
Net Income (ttm)2.72B
Shares Outn/a
EPS (ttm)1.53
PE Ratio95.80
Forward PE14.88
Dividend4.99 (2.63%)
Ex-Dividend DateJul 15, 2025
Volume2,195
Average Volume3,898
Open190.60
Previous Close190.52
Day's Range186.05 - 195.95
52-Week Range159.76 - 218.50
Beta0.48
RSI58.53
Earnings DateJul 25, 2025

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]

Sector Healthcare
Founded 2012
Employees 55,000
Stock Exchange London Stock Exchange
Ticker Symbol 0QCV
Full Company Profile

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD Financial Statements

News

There is no news available yet.